EN DE
Watch Twist Bioscience Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Twist Bioscience Corp (TWST) stock: price, quality, comparison

Price, quality, revenue and earnings and the peer comparison for Twist Bioscience Corp, from audited financials.

Price: $120.79. No valuation: the company's figures do not support a reliable fair value right now, so we deliberately show none.
Price/sales 21.89× (industry 6.08×) · Revenue growth (quarter YoY) 23.2% (industry 0.0%)
  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TB Twist Bioscience Corp logo Thin data Nov 6, 2026

Twist Bioscience Corp

TWST · US
Low debt
Positive coverage
Quality 53/100
Expensive Growth (revenue 5y +33.1 %/yr in USD)
Insiders sold $134.9M (6M)
Loss-making · -31.7% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 12/100 · thin data
Thin data
No fair value
Watch Twist Bioscience Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Which stocks are undervalued right now? Check free Discover now →

Company profile

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.

Show moreShow less

The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.

In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses.

Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody.

The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 95
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 90
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 82
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 77
Distance to the 52-week high, does not count
New shares 44
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 10 officers or directors sold shares worth $134.9M and none bought.

  • SaleRobert F. WernerChief Accounting Officer15× since Nov 21, 2025: 21,925 shares, avg. $67.70$1.5MNov 3, 2026
  • SaleEmily M. LeproustChief Executive Officer, Director27× since Nov 21, 2025: 741,012 shares, avg. $136.52$101.2MNov 3, 2026
  • SalePaula GreenSVP of Human Resources19× since Nov 21, 2025: 89,659 shares, avg. $79.71$7.1MNov 3, 2026
  • SalePatrick John FinnPresident and COO17× since Nov 21, 2025: 236,037 shares, avg. $91.11$21.5MNov 3, 2026
  • SaleDennis ChoOfficer22× since Nov 21, 2025: 84,264 shares, avg. $103.16$8.7MNov 3, 2026
  • SaleAdam LaponisChief Financial Officer14× since Nov 21, 2025: 46,209 shares, avg. $86.90$4.0MOct 9, 2026
  • SaleKatryn BlakeDirector2,240 shares at $122.88$275,251Aug 12, 2026
  • SaleRobert ChessDirector3× since Feb 13, 2026: 30,601 shares, avg. $85.54$2.6MAug 7, 2026
  • SaleMelissa A. StarovasnikDirector4× since Apr 1, 2026: 4,500 shares, avg. $62.76$282,435May 28, 202610b5-1 plan
  • SaleJan JohannessenDirector3× since Nov 18, 2025: 21,244 shares, avg. $44.87$953,322May 12, 2026

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+20.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.1%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−155.5% (2020) → −36.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch TWST, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Twist Bioscience Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Above median
Profitability
Return on assets −12.1% · Below median
Net margin (12 months) −31.7% · Bottom 25%
Operating margin (12 months) −30.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 23.2% · Above median
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 19.99× · Priciest 25%
P/S (12 months) 21.89× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs TWST
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs TWST
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs TWST
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$53.55 +12% vs TWST
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs TWST
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs TWST
argenx SE ARGX $927.21 $908.40 −2% vs TWST
CSL Limited CSL A$202.04 A$183.04 −9% vs TWST
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs TWST
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs TWST

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector

Frequently asked questions

What is the quality score of TWST?
Twist Bioscience Corp has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Twist Bioscience Corp (TWST)?
Twist Bioscience Corp reported trailing-twelve-month revenue of about $432M (latest available figure, as of Nov 6, 2026).
How solid is the balance sheet of Twist Bioscience Corp (TWST)?
Balance-sheet figures for Twist Bioscience Corp (as of Nov 6, 2026): return on equity −29.6%, debt of 0.00 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
Which stocks are comparable to Twist Bioscience Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Twist Bioscience Corp (TWST)?
The closing price on Nov 6, 2026 was $120.79. We carry closing prices from our data provider, not a live tick.

Key figures of Twist Bioscience Corp

How large is the market capitalisation of Twist Bioscience Corp (TWST)?
The market capitalisation of Twist Bioscience Corp is $9.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Twist Bioscience Corp (TWST)?
The price-to-sales ratio of Twist Bioscience Corp is 21.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Twist Bioscience Corp (TWST)?
Earnings per share at Twist Bioscience Corp are $−2.23. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Twist Bioscience Corp (TWST)?
The net margin of Twist Bioscience Corp is −31.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Twist Bioscience Corp (TWST)?
The return on equity (ROE) of Twist Bioscience Corp is −29.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Twist Bioscience Corp (TWST)?
On an EBIT basis the return on assets of Twist Bioscience Corp is −26.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Twist Bioscience Corp (TWST)?
The operating margin of Twist Bioscience Corp is −30.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Twist Bioscience Corp (TWST)?
Revenue at Twist Bioscience Corp is growing +23.2% versus a year earlier (3y avg +22.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Twist Bioscience Corp (TWST) generate?
The free cash flow of Twist Bioscience Corp is −$75.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Twist Bioscience Corp (TWST) hold?
Twist Bioscience Corp holds more cash than debt, $45.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Twist Bioscience Corp in the live analysis

One click puts Twist Bioscience Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.